Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $541.74M |
| Gross Profit (TTM) | $394.97M |
| EBITDA | $104.21M |
| Operating Margin | 16.30% |
| Return on Equity | 6.93% |
| Return on Assets | 3.76% |
| Revenue/Share (TTM) | $6.86 |
| Book Value | $16.50 |
| Price-to-Book | 3.30 |
| Price-to-Sales (TTM) | 8.20 |
| EV/Revenue | 7.45 |
| EV/EBITDA | 35.96 |
| Quarterly Earnings Growth (YoY) | 288.90% |
| Quarterly Revenue Growth (YoY) | 21.50% |
| Shares Outstanding | $79.79M |
| Float | $79.28M |
| % Insiders | 0.54% |
| % Institutions | 113.47% |
Volatility is currently contracting
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will b.
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCYT and any ticker you trade — then tracks every position and per-strategy win rate.
